Chronic hepatitis C is a kind of viral hepatitis caused by hepatitis C virus infection,which can further progress to cirrhosis,liver failure,hepatocellular carcinoma,and even death.Presently,there is no pre-ventive vaccine yet.Therefore,preventing infection and safe and effective drug treatment are currently the most effective strategies for dealing with hepatitis C virus infection.Since 2014,the clinical application of direct-acting antiviral drugs has brought revolutionary changes to the treatment of chronic hepatitis C.Direct-acting antiviral drugs have an excellent hepatitis C virus clearance effect,are well tolerated,have a good safety profile,and can significantly improve liver function,metabolic disorders,immune dysfunction,etc.However,somestudies have pointed out that even if the hepatitis C virus is cleared during the treatment of chronic hepatitis C-related cirrhosis with direct-acting antiviral drugs,a considerable proportion of patients still have severe liver failure,hepatocel-lular carcinoma,and even liver disease-related death,so there are still some problems in the treatment of chronic hepatitis C-related cirrhosis with direct-acting antiviral drugs that need to be further explored.This article reviews the research progress of direct-acting antiviral drugs so as to provide meaningful references for the treatment of patients with chronic hepatitis C-related cirrhosis.
关键词
丙型肝炎病毒/肝硬化/肝细胞癌/肝移植/直接抗病毒药物
Key words
Hepatitis C virus/Liver cirrhosis/Hepatocellular carcinoma/Liver transplantation/Direct-acting antiviral agents
维普
万方数据